



## IBD-BIRD Program

Scientific Group : IBD-BIRD

Day : 12/02/2025

### Wednesday 12.02.2025 PM – Basic and Translational Session

13:30            Satellite Symposium ALFASIGMA

14:00-14:05    Break

#### Session 1

Moderators : Claire Liefferinckx (ULB Erasme), Bram Verstockt (KUL Leuven)

- 14:05    22    I 01    Contrasting outcomes of dietary Interventions and FMT on colonic and ileal inflammation in humanized IBD models. S. DELEU (1), K. VIDMAR (2), S. TROISI (3), H. WARGO (2), L. MASI (3), J. WILLIAMS (2), S. ARTONE (2), S. DE SANTIS (2), C. DE SALVO (2), V. PETITO (3), L. LOPETUSO (4), F. COMINELLI (5), T. PIZARRO (2), F. SCALDAFERRI (3) / [1] Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, DEPARTMENT OF CHRONIC DISEASES, METABOLISM AND AGEING, [2] Case Western Reserve University, Cleveland, the United States, Pathology, [3] Fondazione Policlinico Universitario “A. Gemelli” IRCCS, Rome, Italy, Rome, Italy, CeMAD Translational Research Laboratories, Digestive Disease Center (CeMAD), Department of Medical and Surgical Sciences, [4] “G. d’Annunzio” University of Chieti-Pescara, Chieti, Chieti, Italy, Center for Advanced Studies and Technology (CAST), [5] Case Western Reserve University, Cleveland, the United States, Gastroenterology and hepatology
- 14:16    36    I 02    Total emulsifier intake, but not ultra-processed food consumption is higher in patients with inflammatory bowel disease compared to healthy controls: a Belgian cross-sectional cohort study. J. WELLENS (1), M. DEBRAUWERE (2), S. HOEKX (1), J. VANDERSTAPPEN (1), E. DE MAEGD (2), E. VISSERS (2), M. FERRANTE (1), B. VERSTOCKT (1), S. VERMEIRE (1), J. SABINO (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] KUL – University of Leuven, Leuven, Belgium, Department of Chronic Diseases and

Metabolism, Translational Research Center for Gastrointestinal Disorders (TARGID)

- 14:27 49 I 03 Metagenomic outcomes of faecal microbiota transplantation in ulcerative colitis are influenced by baseline microbial composition and donor-recipient richness disparity.  
S. DELEU (1), J. VAZQUEZ CASTELLANOS (2), S. ANDREU-SÁNCHEZ (2), C. CAENEPEEL (1), S. VERSTOCKT (1), K. ARNAUTS (1), F. BAERT (3), F. MANA (4), L. POUILLON (5), T. LOBATON (6), E. LOUIS (7), D. FRANCHIMONT (8), B. VERSTOCKT (9), M. FERRANTE (9), J. SABINO (9), J. RAES (2), S. VERMEIRE (9) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism, [2] KUL – University of Leuven, Leuven, Belgium, Department of Microbiology and Immunology, [3] AZ Delta, Belgium, Gastroenterology and hepatology, [4] UZ Brussel, Brussels, Belgium, Gastroenterology and hepatology, [5] Imelda Hospital, Bonheiden, Belgium, Gastroenterology and hepatology, [6] University Hospital Ghent (UZ Gent), Gent, Belgium, Gastroenterology and hepatology, [7] CHU Liège, Liège, Belgium, Gastroenterology and hepatology, [8] Erasme Hospital, Brussels, Belgium, Gastroenterology and hepatology, [9] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and hepatology
- 14:38 196 I 04 **Best Basic Abstract:** Multiomic analysis reveals three distinct subtypes within perianal Crohn’s disease, independent of concomitant proctitis.  
S. ABDURAHIMAN (1), J. SABINO (2), S. VERSTOCKT (3), M. FERRANTE (2), M. LENFANT (2), J. RAES (4), A. D’HOORE (5), S. VERMEIRE (2), G. BISLENGHI (5), B. VERSTOCKT (2) / [1] KUL - University of Leuven, Leuven, Belgium, TARGID, [2] KUL - University of Leuven, Leuven, Belgium, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium, [3] KUL - University of Leuven, Leuven, Belgium, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium. , [4] KUL - University of Leuven, Leuven, Belgium, Laboratory of Molecular Bacteriology, Department of Microbiology and Immunology, Rega Institute, KU Leuven, Leuven, Belgium, [5] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Abdominal Surgery, Colorectal Surgery, UZ Leuven, KU Leuven, Leuven, Belgium
- 14:49 **Invited Lecture:** Gut microbiota and its derived metabolites: From biomarkers to targeted prevention and modulation in IBD.  
Harry Sokol (Saint-Antoine Hospital, Sorbonne Université, Paris, France)

15:20-15:50 Coffee Break

## Session 2

Moderators : Sophie Vieujean (CHU Liège), João Sabino (KUL Leuven)

**BIRD** pltch prEsentationS (**BIRDIES**) are ultra-short oral presentations where each investigator has just two minutes to introduce their work. These presentations will not be followed by questions, but you can always approach the presenter during the breaks or view the full E-poster in the exhibition area.

- 15:50 17 I 15 **BIRDIE**: Natural history and MRI predictive factors of radiological healing in fistulising perianal Crohn's disease.  
V. DELMOTTE (1) / [1] CHU Liège, Liège, Belgium, Gastroenterology
- 15:53 33 I 21 **BIRDIE**: The immune cis- regulome: whole blood cell culture - derived response eQTLs reveals potential causative genes in risk loci associated with inflammatory bowel diseases.  
C. LIEFFERINCKX (1) / [1] Erasme Hospital, Brussels, Belgium, Gastro-enterology
- 15:56 58 I 25 **BIRDIE**: Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics– pharmacodynamics study.  
Z. WANG (1) / [1] KUL – University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences
- 15:59 59 I 26 **BIRDIE**: Model-informed dosage de-escalation of infliximab in patients with inflammatory bowel diseases.  
Z. WANG (1) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences
- 16:02 87 I 33 **BIRDIE**: Perianal fistula closure after heterologous mesenchymal stem cell injections is associated with protein levels indicating lower tissue immune infiltrate, specific proteins involved in the control of apoptosis, and probable higher tissues remodeling and proteasome activity.  
M. MEUWIS (1) / [1] CHU of Liège and GIGA institute ULiège, Liège, Belgium, Hepato-Gastroenterology and Digestive Oncology Department and Translational Gastroenterology
- 16:05 197 I 05 The course of Crohn's disease in the biologics era: an in depth single-centre tertiary cohort study in Belgium.  
C. VUCKOVIC (1), A. CREMER (1), L. AMININEJAD (1), C. MINSART (1), J. BOTTIEAU (2), D. FRANCHIMONT (1), C. LIEFFERINCKX (1) / [1] HUB Hôpital Erasme, Brussels, Belgium, Gastroenterology, [2] Laboratoire de Gastro-Entérologie Expérimentale (LGE), Université Libre de Bruxelles, Anderlecht, Belgium, Gastroenterology

- 16:16 56 I 06 Therapeutic antibody clearance better predicts endoscopic outcomes than trough concentrations in patients with Crohn's disease.  
Z. WANG (1), Y. HOFFERT (1), W. ZHANG (1), W. KANTASIRIPITAK (1), V. BRAM (2), J. SABINO (2), M. FERRANTE (2), P. DECLERCK (1), G. D'HAENS (3), D. LAHARIE (4), S. VERMEIRE (2), E. DREESEN (1) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [3] Amsterdam UMC, Amsterdam, the Netherlands, Department of Gastroenterology and Hepatology, [4] Hôpital Haut-Lévêque– Université de Bordeaux, France, Service d'Hépatogastroentérologie et oncologie digestive
- 16:27 66 I 07 Study of the role of the epithelium in the initiation and progression of intestinal fibrosis in ulcerative colitis.  
M. STEPNIAK (1), P. ADAM (1), C. SALÉE (1), C. MASSOT (1), C. SHADOUH (1), S. VIEUJEAN (2), C. REENAERS (2), C. COIMBRA GARCIA MARQUES (3), J. LOLY (2), E. DECKER (3), N. BLÉTARD (4), P. DELVENNE (4), S. SPECA (5), S. BEQ (6), E. LOUIS (2), M. MEUWIS (1) / [1] GIGA Institute, University of Liège, Liège, Belgium, Translational Gastroenterology Research, [2] University Hospital CHU of Liège, Belgium, Hepato-gastroenterology and digestive oncology, [3] University Hospital CHU of Liège, Belgium, Abdominal surgery, [4] University Hospital CHU of Liège, Belgium, Pathological anatomy, [5] University of Lille, Inserm, CHU Lille, France, Infinite unit, [6] Thabor Therapeutics, France, R&D
- 16:38 **Invited Lecture:** The preclinical phases of IBD: Current understanding and future studies.  
Joana Torres (Hospital Beatriz Ângelo, Loures, Universidade de Lisboa, Lisbon, Portugal)
- 17:10-17:15 Break
- 17:15-17:45 Satellite Symposium ABBVIE
- 17:45-18:00 Coffee Break
- 18:00-20:00 BIRD General Assembly

Scientific Group : IBD-BIRD

Day : 13/02/2025

## Thursday 13.02.2025 AM – Clinical Session

08:00-08:30 Breakfast Symposium CELLTRION

08:30-08:35 Break

### Session 3

Moderators: Anneline Cremer (ULB Erasme), Triana Lobaton (UZ Gent)

08:35 **Invited Lecture:** Sequencing therapies in moderate-to-severe UC and acute severe UC.

Anthony Buisson (Centre Hospitalier Universitaire Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France)

- 09:05 34 I 08 Characterisation of remission levels in patients with ulcerative colitis treated with 5-aminosalicylates: Results of the CARUC-ASA prospective multicentre study.  
C. REENAERS (1), C. CAENEPEEL (2), G. LAMBRECHT (3), L. POUILLON (4), F. BAERT (5), A. CREMER (6), A. COLARD (7), C. CLAESSENS (8), T. BILLIET (9), J. GEDOLF (10), B. STRUBBE (11), E. HUMBLET (2), A. DE ZUTTER (12), J. RAHIER (13), M. SOMERS (14), D. REYNDERS (15), L. VANSTEENKISTE (16), I. ARIJS (16), A. RAEVES (16), E. LOUIS (17), B. VERSTOCKT (18) / [1] CHU Liège, Liège, Belgium, gastroenterology, [2] Ziekenhuis Oost Limburg (ZOL), Genk, Belgium, Gastroenterology, [3] AZ Damiaan, Oostende, Belgium, Gastroenterology, [4] Imelda Hospital, Bonheiden, Belgium, Gastroenterology, [5] AZ Delta, Belgium, Gastroenterology, [6] Erasme Hospital, Brussels, Belgium, Gastroenterology, [7] CHC, Liège, Belgium, Gastroenterology, [8] AZ Turnhout, Turnhout, Belgium, Gastroenterology, [9] AZ Groeninge, Kortrijk, Belgium, Gastroenterology, [10] University Hospital Ghent (UZ Gent), Ghent, Belgium, Gastroenterology, [11] AZ Sint-Lucas, Ghent, Belgium, Gastroenterology, [12] Sint Andries ziekenhuis Tielt, Tielt, Belgium, Gastroenterology, [13] CHU Dinant Godinne, Yvoir, Belgium, Gastroenterology, [14] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Gastroenterology, [15] University Hospital Ghent (UZ Gent), Ghent, Belgium, Statistic, [16] BIRD Office, Belgium, BIRD Office, [17] CHU Liège, Liège, Belgium, Gastroenterology, [18] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology
- 09:16 69 I 09 Estimated benefits and willingness of remote monitoring in IBD patients under maintenance therapy.  
D. BEECKMANS (1), S. BRAMS (1), S. DELEN (2), L. FIERENS (3),

M. VANHAVERBEKE (3), J. SABINO (1), B. VERSTOCKT (1), S. VERMEIRE (1), M. FERRANTE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] Ziekenhuis Oost Limburg (ZOL), Genk, Belgium, Department of Gastroenterology and Hepatology, [3] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism

- 09:27 39 I 10 Improved histo-endoscopic outcomes with vedolizumab in early versus late Crohn's disease regardless of disease location: insights from the LOVE-CD trial.  
M. LENFANT (1), G. DE HERTOOGH (2), F. BAERT (3), P. BOSSUYT (4), M. LÖWENBERG (5), E. CLASQUIN (5), F. HOENTJEN (6), T. MOLNÁR (7), G. D'HAENS (5), S. VERMEIRE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and Hepatology, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Pathology, [3] AZ Delta, Belgium, Gastroenterology, [4] Imelda General Hospital, Belgium, Gastroenterology, [5] Amsterdam University Medical Centres, the Netherlands, Gastroenterology, [6] University of Alberta, Alberta, Canada, Gastroenterology, [7] University of Szeged, Szeged, Hungary, Internal Medicine
- 09:38 205 I 11 Endoscopic remission in Crohn's disease, the CREDO trial: Inter-reader variation study of the detection of endoscopic lesions assumed consensually to be related to remission.  
P. BOSSUYT (1), J. MARY (2), E. LOUIS (3), F. BAERT (4), L. CAILLO (5), N. DE SURAY (6), P. DEWINT (7), M. FERRANTE (8), J. FILIPPI (9), D. LAHARIE (10), C. REENAERS (3), M. SIMON (11), C. STEFANESCU (12), C. TRANG (13), L. VUITTON (14), S. VERMEIRE (8), Y. BOUHNİK (12) / [1] Imelda Hospital, Bonheiden, Belgium, Department of gastroenterology, [2] Hospital Saint Louis, France, UMR1153 Inserm CRESS- équipe ECSTRRA-SBIM, [3] CHU Liège, Liège, Belgium, Department of gastroenterology, [4] AZ Delta, Roeselare, Belgium, Department of gastroenterology, [5] CHU Nimes, Nimes, France, Department of gastroenterology, [6] Grand Hôpital de Charleroi, Charleroi, Belgium, Department of gastroenterology, [7] Maria Middelaers Ziekenhuis, Gent, Belgium, Department of gastroenterology, [8] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of gastroenterology and hepatology, [9] CHU Nice, Nice, France, Department of gastroenterology, [10] CHU Bordeaux, France, Department of gastroenterology, [11] Institut Mutualiste Montsouris Paris, Paris, France, Department of gastroenterology, [12] Institut des MICI, France, Department of gastroenterology, [13] CHU Nantes, France, Department of gastroenterology, [14] CHU Besançon, Besançon, France, Department of gastroenterology

09:49 **Invited Lecture:** What's next? Artificial Intelligence in IBD.  
Claire Liefferinckx (Erasme University Hospital, Université Libre de Bruxelles, Bruxelles, Belgium)

10:20-10:50 Coffee Break

#### Session 4

Moderators: Catherine Reenaers (CHU Liège), Peter Bossuyt (Imelda Hospital, Bonheiden)

**BIRD pltch prEsentationS (BIRDIES)** are ultra-short oral presentations where each investigator has just two minutes to introduce their work. These presentations will not be followed by questions, but you can always approach the presenter during the breaks or view the full E-poster in the exhibition area.

- 10:50 170 I 37 **BIRDIE:** Characterization of a European population with recently diagnosed Crohn's Disease: results from the prospective Crohn's Disease Cohort (CROCO) study  
S. VIEUJEAN (1)/ [1] CHU Liège, Liège, Belgium, Department of Gastroenterology,
- 10:53 175 I 38 **BIRDIE:** Evolution of the IBD-Disability Index in a cohort of recently diagnosed CD patients: results from the prospective CROCO (Crohn's Disease Cohort) study.  
A. BUISSON (1) / [1] CHU Clermont – Ferrand, France, IBD Unit
- 10:56 65 I 27 **BIRDIE:** Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab.  
T. HOLVOET (1) / [1] Vitaz, Sint-Niklaas, Belgium, Gastroenterology
- 10:59 29 I 19 **BIRDIE:** Real-life histological remission in Ulcerative colitis patients treated with ustekinumab: results from the Belgian SULTAN trial.  
T. HOLVOET (1) / [1] Vitaz, Sint-Niklaas, Belgium, Gastroenterology
- 11:02 23 I 16 **BIRDIE:** Optimizing patient-reported outcome measurement in an IBD care pathway: results of the PROMOTION study.  
N. LEMBRECHTS (1) / [1] Imelda Hospital, Bonheiden, Belgium, Gastroenterology
- 11:05 188 I 12 Long term real-world effectiveness and safety of upadacitinib in patients with moderate to severe Crohn's disease: a Belgian multi-centric refractory cohort.  
A. PAVLIDI (1), B. VERSTOCKT (2), S. VIEUJEAN (3), V. DESMEDT (4), F. COUTURIER (5), J. RAHIER (6), F. BAERT (7), M. SOMERS (8), O. DEWIT (9), P. BOSSUYT (10), A. HOYOIS (11), T. HOLVOET (12),

R. OUZIEL (13), B. WILLANDT (14), G. LAMBRECHT (15), M. SALAMÉ (16), A. VERRETH (17), M. LENFANT (2), D. FRANCHIMONT (1), A. CREMER (1) / [1] Erasme University Hospital - Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Department of Gastroenterology, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology, [3] University Hospital CHU of Liège, Belgium, Department of Gastroenterology, [4] University Hospital of Ghent, Belgium, Department of Gastroenterology, [5] GZA Sint-Vincentius ziekenhuis, Antwerpen, Belgium, Department of Gastroenterology, [6] CHU-UCL-Namur site Godinne, Yvoir, Belgium, Department of Gastroenterology, [7] AZ Delta, Belgium, Department of Gastroenterology, [8] Antwerp University Hospital, Edegem, Belgium, Department of Gastroenterology, [9] Cliniques universitaires Saint-Luc, Brussels, Belgium, Department of Gastroenterology, [10] Imelda General Hospital, Belgium, Department of Gastroenterology, [11] CHU Saint-Pierre, Brussels, Belgium, Department of Gastroenterology, [12] Vitaz, Sint-Niklaas, Belgium, Department of Gastroenterology, [13] CHU de Charleroi, Hôpital Marie Curie, Charleroi, Belgium, Department of Gastroenterology, [14] AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Department of Gastroenterology, [15] AZ Oostende, Oostende, Belgium, Department of Gastroenterology, [16] CHR De la Haute Senne, Soignies, Belgium, Department of Gastroenterology, [17] AZ Voorkempem, Malle, Belgium, Department of Gastroenterology

11:16 70 I 13 A mindfulness-based intervention has significant effects on depression, stress and perceived control but not on disability in patients with Crohn's disease.  
B. KEERSMAEKERS (1), D. BEECKMANS (1), S. BRAMS (1), K. VANDERBIST (1), M. VAN DEN BOSCH (2), S. VERMEIRE (3), B. VERSTOCKT (3), J. SABINO (3), I. VAN DIEST (4), M. FERRANTE (3) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] KUL – University of Leuven, Leuven, Belgium, Leuven Mindfulness Center, [3] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology, [4] KUL - University of Leuven, Leuven, Belgium, Department of Health Psychology

11:27 53 I 14 **Best Clinical Abstract:** Low remission recapture after ustekinumab dose optimization in Crohn's disease: results of the randomized placebo-controlled double-blind REScUE study.  
P. BOSSUYT (1), J. RAHIER (2), F. BAERT (3), E. LOUIS (4), E. MACKEN (5), T. LOBATON (6), J. BUSSCHAERT (7), H. PEETERS (8), P. DEWINT (9), D. FRANCHIMONT (10), J. DUTRÉ (11), B. WILLANDT (12), C. CLAESSENS (13), O. DEWIT (14), M. FERRANTE (15), S. VERMEIRE (15) / [1] Imelda Hospital, Bonheiden, Belgium, Department of gastroenterology, [2] Centre Hospitalier Universitaire Mont-Godinne, Belgium,



Department of Gastroenterology, [3] AZ Delta, Belgium, Department of Gastroenterology, [4] CHU de Liège, Liège, Belgium, Department of Gastroenterology, [5] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Department of Gastroenterology, [6] University Hospital Ghent (UZ Gent), Gent, Belgium, Department of Gastroenterology, [7] AZ Sint-Lucas Brugge, Assebroek/ Brugge, Belgium, Department of Gastroenterology, [8] AZ Sint-Lucas, Ghent, Belgium, Department of Gastroenterology, [9] AZ Maria Middelaes, Ghent, Belgium, Department of Gastroenterology, [10] Erasme University Hospital, Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Department of Gastroenterology, [11] ZNA Jan Palfijn, Merksem, Belgium, Department of Gastroenterology, [12] AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Department of Gastroenterology, [13] AZ Turnhout, Turnhout, Belgium, Department of Gastroenterology, [14] UCL Saint Luc, Brussels, Belgium, Department of Gastroenterology, [15] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology

11:38 **Invited Lecture:** The Profile Study: From the methodology of selecting reliable prognostic biomarkers to the strategy of biomarker – based patient stratification: What went right or wrong?  
Nurulamin Noor (Cambridge University Hospitals, University of Cambridge, Cambridge, UK)

12:10-12:15 Break

12:15-12:45 Satellite Symposium JANSSEN CILAG /JOHNSON&JOHNSON

12:45-13:30 Lunch

13:30-14:00 Satellite Symposium PFIZER

#### **BIRD E-Posters:**

17 I 15 Natural history and MRI predictive factors of radiological healing in fistulizing perianal Crohn's disease.  
V. DELMOTTE (1), R. GILLARD (2), E. DEFRAIGNE-PEIGNEUR (2), E. LOUIS (1), P. MEUNIER (2), C. REENAERS (3) / [1] CHU Liège, Liège, Belgium, Gastroenterology, [2] CHU Liège, Liège, Belgium, Radiology, [3] CHU Liège, Liège, Belgium, gastroenterology

23 I 16 Optimizing patient-reported outcome measurement in an IBD care pathway: results of the PROMOTION study.  
N. LEMBRECHTS (1), S. LOUIS (1), K. GEERTS (1), K. VAN BRANTEGEM (1), J. DERUA (1), P. BOSSUYT (1), L. POUILLON (1) / [1] Imelda Hospital,

Bonheiden, Belgium, Gastroenterology

- 26 I 17 A risk stratification algorithm to predict relapse during Intravenous-to-subcutaneous switching of infliximab in patients with inflammatory bowel disease.  
R. GARCÉS-DURAN (1), C. SNAUWAERT (2), C. YEUNG (3), H. DANO (4), P. DEPREZ (3) / [1] Cliniques universitaires Saint-Luc, Brussels, Belgium, Gastroenterology, [2] AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Gastroenterology, [3] Cliniques universitaires Saint-Luc, Brussels, Belgium, Gastroenterology, [4] Cliniques universitaires Saint-Luc, Brussels, Belgium, Pathology Department
- 27 I 18 Development and validation of the FR-QoL-29-Dutch (Flemish) questionnaire shows that food-related quality of life is decreased in Crohn's disease, stricturing disease and those with a surgical.  
J. WELLENS (1), L. GUADAGNOLI (2), J. VANDERSTAPPEN (1), S. HOEKX (1), J. VANDAELE (3), M. FERRANTE (1), B. VERSTOCKT (1), K. WHELAN (4), S. VERMEIRE (1), J. SABINO (5) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] Northwestern University Feinberg School of Medicine, IL, the United States, Division of Gastroenterology and Hepatology, [3] Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism, [4] King's College Hospital London, London, the United Kingdom, Department of Nutritional Sciences, [5] University Hospitals Leuven (UZLeuven), Leuven, Belgium, department of Gastroenterology and Hepatology
- 29 I 19 Real-life histological remission in ulcerative colitis patients treated with ustekinumab: results from the Belgian SULTAN trial.  
T. HOLVOET (1), M. TRUYENS (2), C. REENAERS (3), F. BAERT (4), S. VANDENBRANDEN (5), A. CREMER (6), L. POUILLON (7), P. DEWINT (8), W. VAN MOERKERCKE (9), J. RAHIER (10), L. VANDERMEULEN (11), J. VAN DONGEN (12), H. PEETERS (13), G. LAMBRECHT (14), A. VIJVERMAN (15), A. HOORENS (16), A. VAN HAECKE (17), T. LOBATON (18) / [1] Vitaz, Sint-Niklaas, Belgium, Gastroenterology, [2] University Hospital of Ghent, Belgium, Gastroenterology, [3] CHU de Liège, Liège, Belgium, Gastroenterology, [4] AZ Delta, Belgium, Gastroenterology, [5] OLV Aalst, Aalst, Belgium, Gastroenterology, [6] Erasme Hospital, Brussels, Belgium, Gastroenterology, [7] Imelda Hospital, Bonheiden, Belgium, Gastroenterology, [8] AZ Maria Middelaes, Ghent, Belgium, Gastroenterology, [9] AZ Groeninge, Kortrijk, Belgium, Gastroenterology, [10] CHU UCL Namur, Yvoir, Belgium, Gastroenterology, [11] UZ Brussel, Brussels, Belgium, Gastroenterology, [12] AZ Sint Maarten, Mechelen, Belgium, Gastroenterology, [13] AZ Sint-Lucas, Ghent, Belgium, Gastroenterology, [14] AZ Damiaan, Oostende, Belgium, Gastroenterology, [15] CHR Citadelle, Liège, Belgium, Gastroenterology, [16] University

Hospital of Ghent, Belgium, Pathology, [17] Ghent University Hospital, Ghent, Belgium, Pathology, [18] Ghent University Hospital, Ghent, Belgium, Gastroenterology

- 32 I 20 Comparative study of subcutaneous and intravenous infliximab in inflammatory bowel disease: Interim analysis of a prospective single center cohort (the SWITCH study).  
C. LIEFFERINCKX (1), C. MINSART (1), C. HUSSON (2), C. HELMAN (1), V. WAMBACQ (1), L. AMININEJAD (1), A. CREMER (1), D. FRANCHIMONT (1) / [1] HUB Hôpital Erasme, Brussels, Belgium, Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, [2] Université Libre de Bruxelles Faculté de Médecine, Brussels, Belgium, Center for the study of IBD, Laboratory of Experimental Gastroenterology
- 33 I 21 The immune cis- regulome: Whole blood cell culture - derived response eQTLs reveals potential causative genes in Risk Loci associated with Inflammatory bowel diseases.  
C. LIEFFERINCKX (1), D. STERN (2), H. PERÉE (3), A. MAYER (2), C. DUBUSSY (3), E. QUERTINMONT (4), V. TAFCIU (5), C. MINSART (6), V. PETROV (3), W. COPPIETERS (2), L. KARIM (2), S. RAHMOUNI (3), M. GEORGES (3), D. FRANCHIMONT (6) / [1] Erasme Hospital, Brussels, Belgium, Gastro-enterology, [2] GIGA Institute, University of Liège, Liège, Belgium, GIGA Bioinformatics Platform, [3] GIGA Institute, University of Liège, Liège, Belgium, Unit of Animal Genomics, [4] Université libre de Bruxelles, Brussels, Belgium, Laboratory of Experimental Gastroenterology, [5] Université Libre de Bruxelles, Bruxelles, Belgium, Laboratory of Experimental Gastroenterology, [6] HUB Hôpital Erasme, Brussels, Belgium, Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology
- 35 I 22 Distinct involvement of plasma cells and monocytes/macrophages in ileal and colonic ulcer formation in patients with Crohn's disease.  
N. PIERRE (1), N. JACOBS (2), R. FERNÁNDEZ-VERDEJO (3), E. LOUIS (1), S. VIEUJEAN (1) / [1] GIGA Institute, University of Liège, Liège, Belgium, Laboratory of Translational Gastroenterology, [2] GIGA Institute, University of Liège, Liège, Belgium, Cellular and Molecular Immunology, [3] Universidad Finis Terrae, Santiago, Chile, Laboratorio de Fisiología del Ejercicio y Metabolismo (LABFEM)
- 37 I 23 Impact of assay on the predictive performance of model-informed precision dosing of ustekinumab in patients with Crohn's disease.  
W. ZHANG (1), T. DERVIEUX (2), D. THOMAS (1), M. FERRANTE (3), S. VERMEIRE (3), E. DREESEN (1) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences, [2] Prometheus Laboratories, the United States, Prometheus Laboratories, [3] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology

- 40 I 24 Unravelling genetic versus environmental factors determining disease course in IBD: a population-based cohort study in first- and second-generation immigrants.  
A. D'HOOOGHE (1), G. JUUL POULSEN (1), C. NIKOLAI SØRENSEN (1), P. TANDON (2), N. NYBOE ANDERSEN (3), S. VERMEIRE (4), B. VERSTOCKT (4), T. JESS (1) / [1] Aalborg University, Denmark, Center for Molecular Prediction of Inflammatory Bowel Disease, PREDICT, Department of Clinical Medicine, [2] University of Toronto, Canada, Division of Gastroenterology and Hepatology, University Health Network, [3] Zealand University Hospital, Koge, Denmark, Department of Gastroenterology and Hepatology, [4] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology
- 58 I 25 Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics–pharmacodynamics study.  
Z. WANG (1), M. FERRANTE (2), S. VERMEIRE (2), E. DREESEN (1) / [1] KUL – University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology
- 59 I 26 Model-informed dosage de-escalation of infliximab in patients with inflammatory bowel diseases.  
Z. WANG (1), I. DE GREEF (2), W. KANTASIRIPITAK (1), S. WICHA (3), S. TOPS (1), M. NIGRO (2), A. OUTTIER (2), B. VERSTOCKT (2), J. SABINO (2), D. THOMAS (1), S. VERMEIRE (2), M. FERRANTE (2), E. DREESEN (4) / [1] KUL - University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [3] University of Hamburg, Germany, Department of Clinical Pharmacy, [4] KUL - University of Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology
- 65 I 27 Subcutaneous infliximab in IBD patients previously treated with an optimized intravenous infliximab dosing schedule: preliminary results on expectations and satisfaction of switching from intravenous to subcutaneous infliximab.  
T. HOLVOET (1), A. MOENS (2), P. BOSSUYT (3), T. LOBATON (4), A. POSEN (5), A. CREMER (6), L. CAPIRCHIO (7), C. CAENEPEEL (8), G. LAMBRECHT (9), A. AMEZAGA (10), C. REENAERS (11), H. PEETERS (12), B. WILLANDT (13), N. DEPRez (14), J. DE RECHTER (15), I. ARIJS (15), N. STRAETEMANS (5), E. DREESEN (16), BELGIAN RESEARCH AND DEVELOPMENT (15), M. FERRANTE (17) / [1] Vitaz, Sint-Niklaas, Belgium, Gastroenterology, [2] Heilig Hartziekenhuis Lier, Lier, Belgium, Gastroenterology, [3] Imelda Hospital, Bonheiden, Belgium, Gastroenterology, [4] Ghent University Hospital, Ghent, Belgium, Gastroenterology, [5] AZ Vesalius Tongeren, Tongeren, Belgium,

Gastroenterology, [6] Erasme University Hospital - Université Libre de Bruxelles (ULB), Bruxelles, Belgium, Gastroenterology, [7] Chwapi, tournai, Belgium, Gastroenterology, [8] Ziekenhuis Oost Limburg (ZOL), Genk, Belgium, Gastroenterology, [9] AZ Damiaan, Oostende, Belgium, Gastroenterology, [10] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, Gastroenterology, [11] CHU de Liège, Liège, Belgium, Gastroenterology, [12] AZ Sint-Lucas, Ghent, Belgium, Gastroenterology, [13] AZ Sint-Jan Brugge-Oostende, Brugge, Belgium, Gastroenterology, [14] AZ Maria Middelaes, Ghent, Belgium, Gastroenterology, [15] BIRD vzw - Belgian IBD Research and Development, Zaventem, Belgium, BIRD, [16] KUL - University of Leuven, Leuven, Belgium, Pharmaceutical and Pharmacological Sciences, [17] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology

- 68 I 28 Treatment persistence, clinical, and biological outcomes following an elective switch from intravenous to subcutaneous infliximab and vedolizumab.  
A. OUTTIER (1), Y. HOFFERT (2), E. DE DYCKER (1), P. GEENS (1), T. LAMBRECHTS (1), E. LODDEWIJKX (1), A. PAPS (1), B. VERSTOCKT (1), J. SABINO (1), S. VERMEIRE (1), M. FERRANTE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology, [2] KUL – University of Leuven, Leuven, Belgium, Department of Pharmaceutical and Pharmacological Sciences
- 71 I 29 Comprehensive IBD Care: Introduction of an IBD-specialized psychologist in a multidisciplinary IBD team.  
B. KEERSMAEKERS (1), K. VANDERBIST (2), S. VERMEIRE (3), B. VERSTOCKT (3), J. SABINO (3), M. FERRANTE (3) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [3] University Hospitals Gasthuisberg, Leuven and KU Leuven, Leuven, Belgium, Department of Gastroenterology and Hepatology
- 76 I 30 Validation of an acute murine model of inflammation to study the interest of bio-active peptide hydrolysates.  
C. CAUWELIER (1), A. NEYRINCK (1), G. THIRION (2), P. STORDEUR (2), P. FILÉE (3), N. DELZENNE (1), D. TORRES (3) / [1] Université catholique de Louvain (UCLouvain), Belgium, LDRI, [2] CERgroupe, Marche-en-Famenne, Belgium, Preclinical and pharming, [3] CERgroupe, Marche-en-Famenne, Belgium, Immunobiology Laboratory
- 81 I 31 Proteomic profiles associated with residual ultrastructural anomalies in the epithelium of IBD patients in endoscopic remission.  
M. MEUWIS (1), J. LOLY (2), C. SALÉE (3), C. MASSOT (3), D. BAIWIR (4), M. FLÉRON (5), G. MAZZUCHELLI (6), S. VIEUJEAN (7), J. SOMJA (8), E. LOUIS (9) / [1] CHU of Liège and GIGA institute ULiège, Liège, Belgium,

Hepato-Gastroenterology and Digestive Oncology Department, Translational gastroenterology laboratory, [2] CHU de Liège, Liège, Belgium, Hepato-gastroenterology and digestive oncology, [3] GIGA Institute, University of Liège, Liège, Belgium, Translational gastroenterology laboratory, [4] University of Liège, Liège, Belgium, GIGA Proteomics Facility, [5] University of Liège, Liège, Belgium, GIGA Proteomics Facility, [6] University of Liège, Liège, Belgium, Laboratory of mass spectrometry, [7] CHU of Liège, GIGA institute ULiège, CHRU Nancy, Liège, Belgium, Hepato-gastroenterology and digestive oncology, Translational gastroenterology laboratory, Gastroentreology dep INSERM, [8] CHU de Liège, Liège, Belgium, Department of Pathology, [9] CHU of Liège and GIGA institute ULiège, Liège, Belgium, Hepato-gastroenterology and digestive oncology, Translational gastroenterology laboratory

- 82 I 32 Development of novel inflammatory and ER stress mixes to simulate IBD phenotypes in differentiated intestinal organoids.  
L. GIORIO (1), K. ARNAUTS (1), J. SABINO (2), M. FERRANTE (2), S. VERMEIRE (2), B. VERSTOCKT (2) / [1] KUL - University of Leuven, Leuven, Belgium, Translational Research Center for Gastrointestinal Disorders TARGID, CHROMETA, [2] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology
- 87 I 33 Perianal fistula closure after heterologous mesenchymal stem cell injections is associated with protein levels indicating lower tissue immune infiltrate, specific proteins involved in the control of apoptosis, and probable higher tissues remodeling and proteasome activity  
M. MEUWIS (1), D. BAIWIR (2), M. FLÉRON (2), G. MAZZUCHELLI (3), L. BOUTAFFALA (4), C. REENAERS (4), C. VAN KEMSEKE (4), S. VIEUJEAN (5), V. BETTONVILLE (6), A. BRIQUET (6), C. LECHANTEUR (6), C. COIMBRA MARQUES (7), E. LOUIS (8) / [1] CHU of Liège and GIGA institute ULiège, Liège, Belgium, Hepato-Gastroenterology and Digestive Oncology Department and Translational Gastroenterology, [2] University of Liège, Liège, Belgium, GIGA Proteomics Facility, [3] University of Liège, Liège, Belgium, Laboratory of mass spectrometry, [4] CHU Liège, Liège, Belgium, Hepato-gastroenterology and digestive oncology, [5] CHU of Liège, GIGA institute ULiège, CHRU Nancy, Liège, Belgium, Hepato-gastroenterology and digestive oncology, Translational gastroenterology laboratory, Gastroentreology dep INSERM, [6] CHU Liège, Liège, Belgium, LTCG Division of Hematology, [7] CHU Liège, Liège, Belgium, Abdominal, Senology, Endocrine surgery and Transplantation, [8] CHU of Liège and GIGA institute ULiège, Liège, Belgium, Hepato-gastroenterology and digestive oncology Department and Translational gastroenterology laboratory

- 93 I 34 Is it possible to have inflammatory bowel disease and fatty liver? The results of a single-centre study in a Belgian secondary hospital. M. MAISIN (1), B. DE VROEY (2), O. DESCAMPS (3), J. GHILAIN (2), O. DEWIT (1), N. LANTHIER (1) / [1] Cliniques universitaires Saint-Luc, Woluwe-Saint-Lambert, Belgium, Gastroentérologie, [2] Hôpital de Jolimont, Haine-Saint-Paul, Belgium, Gastroentérologie, [3] Hôpital de Jolimont, Haine-Saint-Paul, Belgium, Médecine interne
- 125 I 35 Intestinal ultrasound correlates with patient-reported IBD disability in ulcerative colitis: A step towards integrated monitoring. E. EGGERMONT (1), M. LENFANT (1), L. FIERENS (2), S. VERMEIRE (1), M. FERRANTE (1), J. SABINO (1), B. VERSTOCKT (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [2] Translational Research Center for Gastrointestinal Disorders (TARGID), KULeuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism (CHROMETA)
- 135 I 36 Development of a patient-centred dashboard for routine IBD monitoring. L. FIERENS (1), C. HEDIN (2), G. NOVACEK (3), M. JULSGAARD (4), E. GROSS (5), I. ARIJS (6), C. SANDER (7), V. VAKOUFTSI (8), J. KOENDERS (9), M. VANHAVERBEKE (1), T. STAMM (10), M. FERRANTE (11) / [1] KUL – University of Leuven, Leuven, Belgium, Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism (CHROMETA), [2] Karolinska Institutet, Karolinska University Hospital, Sweden, Department of Medicine Solna, [3] Medical University of Vienna, Vienna, Austria, Department of Internal Medicine III, [4] Aarhus University Hospital, Aarhus, Denmark, Aarhus, Denmark, Department of Hepatology and Gastroenterology, [5] Österreichische Morbus Crohn / Colitis ulcerosa Vereinigung (ÖMCCV), Austria, Österreichische Morbus Crohn / Colitis ulcerosa Vereinigung (ÖMCCV), [6] Belgian IBD Research and Development (BIRD), Belgium, Belgian IBD Research and Development (BIRD), [7] Deutsche Morbus Crohn/Colitis ulcerosa Vereinigung (DCCV e.V.), Germany, Referat Wissenschaft, [8] Hellenic Society of Crohn's disease and ulcerative colitis patients (HELLESCC), Greece, Hellenic Society of Crohn's disease and ulcerative colitis patients (HELLESCC), [9] Takeda Pharmaceuticals International AG, the Netherlands, Health Data partnerships / New Product Planning Centraal & Oost Europa, [10] Medical University of Vienna, Vienna, Austria, Institute for Outcomes Research, Center for Medical Data Science, [11] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology
- 170 I 37 Characterization of a European population with recently diagnosed Crohn's Disease: results from the prospective Crohn's Disease Cohort (CROCO) Study. S. VIEUJEAN (1), L. MONIN (1), J. REVÉS (2), N. AREBI (3), A. FADRA (4),

J. BURISCH (5), GR. MADSEN (5), B. ANTHONY (6), M. DODEL (7), M. CRAVO (8), D. DURICOVA (9), P. ELLUL (10), I. KAIMAKLIOTIS (11), S. SHAJI (12), I. ORDAS (13), I. RODRÍGUEZ-LAGO (14), I. MOCANU (15), V. HERNANDEZ (16), M. NACHURY (17), M. FUMERY (18), A. GOLDIS (19), N. PEDERSEN (20), D. CONCEIÇÃO (21), B. BARBERIO (22), A. GUEDES (23), R. RIBEIRO (24), R. UNGARO (25), J. MARY (26), N. BIGOT (27), J. LAMBERT (28), COLOMBEL (29), J. TORRES (30) / [1] CHU Liège, Liège, Belgium, Department of Gastroenterology, [2] Hospital Beatriz Ângelo, Loures, Portugal, Division of Gastroenterology, [3] St Mark's National Bowel Hospital, the United Kingdom, Department of IBD, [4] St Mark's National Bowel Hospital, the United Kingdom, Department of IBD, [5] Copenhagen University Hospital - Amager and Hvidovre, Denmark, Gastroint Medical Division, [6] CHU Clermont - Ferrand, France, IBD Unit, [7] CHU Clermont - Ferrand, France, IBD Unit, [8] Hospital da Luz- Luz Saúde, Portugal, Division of Gastroenterology, [9] ISCARE a.s., the Czech Republic, IBD Clinical and Research Clinic, [10] Mater dei hospital, Malta, Department of Gastroenterology, [11] American Gastroenterology Center, Cyprus, American Gastroenterology Center, Gastroenterologie and Hepatologist, Strovolos- Cyprus, Cyprus, [12] Hull University Teaching Hospitals, BD Research Unit, the United Kingdom, Department of Gastroenterology, Hull, United Kingdom, [13] Hospital Clinic Barcelona- IDIBAPS- CIBER-EHD, Spain, IBD Unit- Department of Gastroenterology, [14] Hospital Universitario de Galdakao- Biobizkaia Health Research Institute, Spain, Department of Gastroenterology, Galdakao, Spain, [15] Hospital Garcia de Orta, Portugal, Department of Gastroenterology, Almada, Portugal, [16] Hospital Alvaro Cunqueiro, Spain, Gastroenterologie, [17] Univ. Lille- Inserm- CHU Lille- U1286 - INFINITE, France, Institute for Translational Research in Inflammation, Lille, France, [18] CHU Amiens-Picardie Hôpital Sud, France, Department of Hepato – Gastroenterology, [19] Algomed Policlinic, Romania, Algomed Policlinic, Gastroenterologie, Timisoara, Romania, [20] Slagelse Hospital, Denmark, Slagelse Hospital, Gastroenterologie, Slagelse, Denmark, [21] Instituto Português de Oncologia de Lisboa, Lisbon, Portugal, Division of Gastroenterology, [22] University of Padua, Padua, Italy, Division of Gastroenterology- Department of Surgery- Oncology and Gastroenterology, [23] Hospital da Luz Learning Health- Luz Saúde, Portugal, Hospital da Luz Learning Health- Luz Saúde, Research Centre, Lisboa, Portugal, [24] Hospital da Luz Learning Health- Luz Saúde, Portugal, Research Centre, [25] Mount Sinai Hospital, the United States, Department of Gastroenterology, [26] Centre of Research in Epidemiology and Statistics- UMR 1153- Inserm, France, Centre of Research in Epidemiology and Statistics- UMR 1153- Inserm, ECSTRRA Unit, Paris, France, [27] Centre of Research in Epidemiology and Statistics- UMR 1153-Inserm, France, 28ECSTRRA Unit, [28] Centre of Research in Epidemiology and Statistics- UMR 1153- Inserm, France, ECSTRRA Unit, [29] Mount Sinai Hospital, the United States, Department of Gastroenterology, [30] Hospital Beatriz Ângelo, Loures, Portugal, Division of Gastroenterology



Evolution of the IBD-Disability Index in a cohort of recently diagnosed CD patients: results from the prospective CROCO (Crohn's Disease Cohort) study.

A. BUISSON (1), M. DODEL (1), J. REVÉS (2), J. BURISCH (3), G. MADSEN (4), N. AREBI (5), A. FADRA (5), S. VIEUJEAN (6), L. MONIN (6), M. CRAVO (7), D. DURICOVA (8), P. ELLUL (9), I. KAIMAKLIOTIS (10), S. SHAJI (11), O. INGRID (12), I. RODRÍGUEZ-LAGO (13), I. MOCANU (14), V. HERNANDEZ (15), M. NACHURY (16), M. FUMERY (17), A. GOLDIS (18), N. PEDERSEN (19), D. CONCEIÇÃO (20), B. BARBERIO (21), A. GUEDES (22), R. RIBEIRO (23), R. UNGARO (24), J. MARY (25), N. BIGOT (25), J. LAMBERT (25), J. COLOMBEL (26), J. TORRES (2) / [1] CHU Clermont – Ferrand, France, IBD Unit, [2] Hospital Beatriz Ângelo, Loures, Portugal, Division of Gastroenterology, [3] Copenhagen University Hospital – Amager and Hvidrove, Denmark, Copenhagen University Hospital - Amager and Hvidrove, Gastrounit Medical Division, Hvidovre, Denmark, [4] Copenhagen University Hospital - Amager and Hvidovre, Denmark, Gastrounit Medical Division, [5] St Mark's National Bowel Hospital, the United Kingdom, Department of IBD, [6] CHU Liège, Liège, Belgium, Department of Gastroenterology, [7] Hospital da Luz- Luz Saúde, Portugal, Division of Gastroenterology, [8] ISCARE a.s., the Czech Republic, IBD Clinical and Research Clinic, [9] Mater dei hospital, Malta, Department of Gastroenterology, [10] American Gastroenterology Center, Cyprus, Gastroenterologie and Hepatologist, [11] Hull University Teaching Hospitals, BD Research Unit, the United Kingdom, IBD Research Unit- Department of Gastroenterology, [12] Hospital Clinic Barcelona- IDIBAPS- CIBER-EHD, Spain, IBD Unit- Department of Gastroenterology, [13] Hospital Universitario de Galdakao- Biobizkaia Health Research Institute, Spain, Department of Gastroenterology, [14] Hospital Garcia de Orta, Portugal, Department of Gastroenterology, [15] Hospital Alvaro Cunqueiro, Spain, Gastroenterologie, [16] Univ. Lille- Inserm- CHU Lille- U1286 - INFINITE, France, Institute for Translational Research in Inflammation, [17] CHU Amiens-Picardie Hôpital Sud, France, Department of Hepato - Gastroenterology, [18] Algomed Policlinic, Romania, Gastroenterologie, [19] Slagelse Hospital, Denmark, Gastroenterologie, [20] Instituto Português de Oncologia de Lisboa, Lisbon, Portugal, Division of Gastroenterology, [21] University of Padua, Padua, Italy, Division of Gastroenterology- Department of Surgery- Oncology and Gastroenterology, [22] Hospital da Luz Learning Health- Luz Saúde- Lisboa- Portugal, Portugal, Research Department, [23] Hospital da Luz Learning Health- Luz Saúde, Portugal, Research Department, [24] Icahn School of Medicine at Mount Sinai, the United States, Department of Gastroenterology, [25] Centre of Research in Epidemiology and Statistics- UMR 1153- Inserm, France, ECSTRRA Unit, [26] Mount Sinai Hospital, the United States, Department of Gastroenterology

- 198 I 39 The prevalence and causes of chronic liver biochemistry abnormalities among patients with inflammatory bowel disease.  
F. HARDUIN (1), W. KWANTEN (2), M. SOMERS (3), E. MACKEN (3), L. VONGHIA (2), J. DERDEYN (2), T. STEINHAUSER (2), T. VANWOLLEGHEM (2), S. FRANcqUE (4), A. JAUREGUI AMEZAGA (3) / [1] Cliniques universitaires Saint-Luc, Brussels, Belgium, Gastro-enterologie, [2] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, hepatology, [3] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, gastroenterology, [4] UZA, Universitair Ziekenhuis Antwerpen, Edegem, Belgium, gastroenterology and hepatology
- 204 I 40 Speed of disease progression as hallmark of Crohn's disease severity: The rapid and slow progressors.  
C. VUCKOVIC (1), A. CREMER (1), L. AMININEJAD (1), C. MINSART (1), J. BOTTIEAU (2), D. FRANCHIMONT (1), C. LIEFFERINCKX (1) / [1] HUB Hôpital Erasme, Brussels, Belgium, Gastroenterology, [2] Laboratoire de Gastro-Entérologie Expérimentale (LGE), Université Libre de Bruxelles, Anderlecht, Belgium, Gastroenterology
- 206 I 41 A clustering approach to discriminate slow and rapid biologics switchers in difficult-to-treat Crohn's disease patients.  
C. VUCKOVIC (1), A. CREMER (1), L. AMININEJAD (1), C. MINSART (1), J. BOTTIEAU (2), D. FRANCHIMONT (1), C. LIEFFERINCKX (1) / [1] HUB Hôpital Erasme, Brussels, Belgium, Gastroenterology, [2] Laboratoire de Gastro-Entérologie Expérimentale (LGE), Université Libre de Bruxelles, Anderlecht, Belgium, Gastroenterology
- 207 I 42 Long-term effectiveness and treatment persistence of ustekinumab based on its positioning in the treatment line for Crohn's disease.  
M. BROGNET (1), C. LIEFFERINCK (1), R. MARÉCHAL (2), D. FRANCHIMONT (1), A. CREMER (1) / [1] Erasme Hospital, Brussels, Belgium, Gastroenterology, [2] CHU Tivoli, La Louvière, Belgium, Gastroenterology
- 210 I 43 Bile acid profiling of ileal fluid in Crohn's disease using metabolomics.  
I. DE GREEF (1), S. LOOPMANS (2), G. BISLENGHI (3), A. D'HOORE (3), I. TERRASSON (3), B. VERSTOCKT (4), J. SABINO (4), M. FERRANTE (4), B. GHESQUIÈRE (2), S. VERMEIRE (4), S. VERSTOCKT (5) / [1] KUL – University of Leuven, Leuven, Belgium, Chronic Diseases and Metabolism (CHROMETA), [2] KUL - University of Leuven, Leuven, Belgium, Department of Cellular and Molecular Medicine, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Abdominal surgery, [4] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Department of Gastroenterology and Hepatology, [5] KUL - University of Leuven, Leuven, Belgium, Department of Chronic Diseases and Metabolism

231 I 44 Optimizing care for women of childbearing age with inflammatory bowel disease: Developing a specific pathway utilizing European Crohn's and Colitis Organization guidelines and the American Gastroenterology Association recommendations.  
E. DE DYCKER (1), P. GEENS (1), T. LAMBRECHTS (1), E. LODDEWIJKX (1), A. PAPS (1), J. DEGRY (2), C. D'HONDT (3), A. MATTHIJS (3), S. VERMEIRE (1), J. SABINO (1), B. VERSTOCKT (1), L. LANNOO (3), K. VAN CALSTEREN (3), M. FERRANTE (1) / [1] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Gastroenterology and Hepatology, [2] KUL – University of Leuven, Leuven, Belgium, Chronic Diseases and Metabolism, [3] University Hospitals Leuven (UZLeuven), Leuven, Belgium, Obstetrics and Gynaecology